NICOYA年衍药业
/
Back to newsroom
R&D milestone

Calcifediol program reaches a China IND submission milestone

In February 2023, Nicoya notified EirGen of an IND submission to China's Center for Drug Evaluation.

Submission milestone

OPKO's filing with the U.S. SEC states that, in February 2023, Nicoya notified EirGen of an investigational new drug submission to China's Center for Drug Evaluation, triggering a contractual milestone.

What the milestone means

An IND submission is one step in research and regulatory dialogue. It does not mean that a product has been approved or may be sold. Its status should be read against formal company and regulatory disclosures.

Further information

Follow formal company and regulatory updates for subsequent progress. Study design, intended settings, benefits and risks should be understood from materials appropriate to each stage.

View original sourceU.S. SEC · OPKO annual filing ↗